Advertisement

Endometrial Carcinoma and its Precursors

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1242)

Abstract

This chapter focuses on premalignant and malignant diseases of the endometrium (lining of the uterus). Endometrial carcinoma is the most common gynecologic cancer in the United States. Women have a 1 in 40 lifetime risk of being diagnosed with endometrial cancer, the fourth most common malignancy among women. An estimated 61,880 new diagnoses of uterine cancer and 12,160 deaths from the disease occurred in 2019 in the United States (American Cancer Society, Facts & Figures, https://www.cdc.gov/cancer/uterine/statistics/index.htm, 2019).

Keywords

Ovarian cancer Pathophysiology Genetics Management Histology Treatment Surveillance 

References

  1. 1.
    Sponholtz T, Palmer J, Rosenberg L, Hatch E, Adams-Campbell L, Wise L. Reproductive factors and incidence of endometrial cancer in U.S. black women. Cancer Causes Control. 2017;28(6):579–88.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Setiawan V, Yang H, Pike M, McCann S, Yu H, Xiang Y, Wolk A. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Deligdisch L, Marin T, Melana S, Mandel J, Holland JF, Pogo B. Human mammary tumor virus (HMTV) in endometrial carcinoma. Int J Gynecol Cancer. 2013;23:1423–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10.PubMedCrossRefGoogle Scholar
  5. 5.
    Lewin S, Herzog T, Barrena MN, Deutsch I, Burke W, Sun X, Wright J. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Grice J, Ek M, Greer B, Koh W, Muntz H, Cain J, Tamimi H, Stelzer K, Figge D, Goff B. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69(1):69–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Damle R, Dravid N, Suryawanshi K, Gadre A, Bagale P, Ahire N. Clinicopathological Spectrum of endometrial changes in peri-menopausal and post-menopausal abnormal uterine bleeding: a 2 years study. J Clin Diagn Res. 2013;7(12):2774–6.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Kendall B, Ronnett B, Isacson C, Cho K, Hedrick L, Diener-West M, Kurman R. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012.PubMedCrossRefGoogle Scholar
  9. 9.
    Deligdisch L, Cohen CJ. Histologic correlates and virulence implication of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. 1985;56:1452.PubMedCrossRefGoogle Scholar
  10. 10.
    Fox H, Buckley C. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology. 1982;6:493.PubMedCrossRefGoogle Scholar
  11. 11.
    Emons G, Beckmann M, Schmidt D, P. Mallmann and Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015;75(2):135–6.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Gallos I, Ganesan R, Gupta J. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121(6):1165–71.PubMedCrossRefGoogle Scholar
  13. 13.
    ACOG Practice Bulletin. Management of endometrial cancer. Obstet Gynecol. 2005;65.Google Scholar
  14. 14.
    Gal D, Edman C, Vellios F, Forney J. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol. 1983;143(3):316–22.CrossRefGoogle Scholar
  15. 15.
    Cade T, Quinn M, Rome R, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7):879–84.PubMedCrossRefGoogle Scholar
  16. 16.
    Kurman R, Carcangiu M, Herrington C, R. E. Young and World Health Organization. WHO classification of tumours of the female reproductive organs. 2014. pp. 126–50.Google Scholar
  17. 17.
    Brinton L, Felix A, McMeekin D, Creasman W, Sherman M, Mutch D, Cohn D, Walker J, Moore R, Downs L, Soslow R, Zaino R. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129(2):277–84.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Creasman W, DeGeest K, DiSaia P, Zaino R. Significance of true surgical pathologic staging: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1999;181:31–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Deligdisch L, Kase NG, Bleiweiss IJ. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology. 2000a;46:17–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Vargas R, Rauh-Hain J, Clemmer J, Clark R, Goodman A, Growdon W, Schorge J, Del Carmen M, Horowitz N, Boruta DN. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014;133(2):216–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Creasman W. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol. 1991;77(2):308–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Creasman W, Henderson D, Hinshaw W, Clarke-Pearson D. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986;67(3):326–30.PubMedGoogle Scholar
  23. 23.
    Dieudonne AS, Lambrechts D, Smeets D, Belmans A, Wildiers H, Paridaens R, Hyonil C, Timmerman D, Christiaens MR, Vergote I, Neven P. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in post-menopausal women on tamoxifen. Ann Oncol. 2014;25:90–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Hrstka R, Podhorec J, Nenutil R, Sommerova L, Obacz J, Durech M, Faktor J, Bouchal P, Skoupilova H, Vojtesek B. Tamoxifen-dependent induction of AGR2 is associated with increased aggressiveness of endometrial Cancer cells. Cancer Investig. 2017;35:313–24.CrossRefGoogle Scholar
  25. 25.
    Magriples U, Naftolin F, Schwartz PE, Carcangiu M. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin Oncol. 1993;11:485–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Robinson DC, Bloss JD, Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol. 1995;59:186–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Deligdisch L, Kalir T, Cohen CJ, De Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Pathol. 2000b;78:181–6. Selected for Breast Diseases: A Yearbook Quarterly 2001, publ. Mosby Yearbook Inc.Google Scholar
  28. 28.
    Clark T, Barton P, Coomarasamy A, Gupta J, Khan K. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG. 2006;113:502.PubMedCrossRefGoogle Scholar
  29. 29.
    Dijkhuizen F, Mol B, Brölmann H, Heintz A. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765.PubMedCrossRefGoogle Scholar
  30. 30.
    Torres M, Weaver A, Kumar S, Uccella S, Famuyide A, Cliby W, Dowdy S, Gostout B, Mariani A. Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol. 2012;120(5):998–1004.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Hwang J, Kim D, Bae H, Kim M, Jung Y, Yun B, Seong S, Shin E, Kim M. Combined oral medroxyprogesterone/Levonorgestrel-intrauterine system treatment for women with grade 2 stage IA endometrial Cancer. Int J Gynecol Cancer. 2017;27(4):738.PubMedCrossRefGoogle Scholar
  32. 32.
    Park J, Kim D, Kim T, Kim J, Kim J, Kim Y, Kim Y, Bae D, Nam J. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol. 2013;122(1):7–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Wárlám-Rodenhuis C, De Winter K, Lutgens L, van den Bergh A, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355(9213):1404–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Khoury-Collado F, Murray M, Hensley M, Sonoda Y, Alektiar K, Levine D, Leitao M, Chi D, Barakat R, Abu-Rustum N. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to the regional lymph nodes. Gynecol Oncol. 2011;122(2):251–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Obermair A, et al. Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer. 1999;9:383–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Deleon M, Ammakkanavar N, Matei D. Adjuvant therapy for endometrial cancer. J Gynecol Oncol. 2014;25(2):136–47.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Creutzberg C, van Putten W, Koper P, Lybeert M, Jobsen J, Wárlám-Rodenhuis C, De Winter K, Lutgens L, van den Bergh A, van der Steen-Banasik E, Beerman H, van Lent M, PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89(2):201–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Gunderson C, Fader A, Carson K, Bristow R. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477.PubMedCrossRefGoogle Scholar
  39. 39.
    American Cancer Society. American Cancer Society. Facts & Figures. 2019. https://www.cdc.gov/cancer/uterine/statistics/index.htm

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Robert Wood Johnson Barnabas Health Newark Beth Israel Medical CenterNewarkUSA
  2. 2.Nezhat Surgery for Gynecology/OncologyNew YorkUSA
  3. 3.Weill Cornell Medical College of Cornell UniversityNew YorkUSA
  4. 4.Stony Brook University School of MedicineStony BrookUSA
  5. 5.Department of Minimally Invasive Gynecologic Surgery and Robotics, NYU Winthrop University HospitalMineolaUSA

Personalised recommendations